Improved Brain Insulin/Insulin-like Growth Factor Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer’s Disease

Manuscript Number: 

16-0656R1

Author(s): 
John Didsbury, Irio Schiano, Ming Tong, Suzanne M. de la Monte

Disclosures

Suzanne M. de la Monte

  • Equity:
    T3D stock options
    Lecture Fees:
    Novo Nordisk--keynote lecture

John Didsbury

  • Equity:
    Founder & CEO T3D Therapeutics, Inc.
    Patents/Royalties
    hold patent on T3D-959

Irio Schiano

  • Nothing to Disclose

Ming Tong

  • Nothing to Disclose